BRABANT PHARMA
Brabant Pharma is a single purpose company developing an oral treatment (“Brabafen”) suitable for use in children with Dravet Syndrome (otherwise known as severe myoclonic epilepsy of infancy). Dravet Syndrome is a rare form of childhood epilepsy associated with catastrophic seizures resulting in mental and cognitive impairment. Approximately 10%-15% of children die as a direct result. Patients are unresponsive to normal anticonvulsants. Based on the incidence of Dravet Syndrome, the n... ew treatment will qualify as an Orphan Product in Europe and the United States (US), receiving data exclusivity for 10 and 7 years respectively. Brabant has licensed exclusive access to new clinical data using up to 20 years of case studies showing exceptional efficacy for the treatment in children with Dravet Syndrome which are frequently unresponsive to standard anticonvulsants.
BRABANT PHARMA
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Hanoi, NA - Vietnam, Vietnam
Country:
Vietnam
Website Url:
http://www.brabantpharma.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
GlaucoPharm
GlaucoPharm is developing TG-46, a novel topical treatment for glaucoma.
VersaPeutics
VersaPeutics is a biotech startup devoted to finding treatment for disorders of the nervous system.
ViAqua Therapeutics
ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.
Investors List
Aquarius Equity Partners
Aquarius Equity Partners investment in Venture Round - Brabant pharma
Official Site Inspections
http://www.brabantpharma.com
- Host name: 103.56.161.59
- IP address: 103.56.161.59
- Location: Vietnam
- Latitude: 16.0023
- Longitude: 105.9999
- Timezone: Asia/Ho_Chi_Minh
